Singapore Institute of Advanced Medicine Holdings (9G2) Fair Value & Analysis
Healthcare · SG · Market cap 48.3M SGD
Fair value as of: Jul 4, 2026
From 1 valuation models · updated today
Share price −20.0% over the past month.
Price vs Fair Value (12 months)
12‑month range 0.0260 SGD – 0.0800 SGD · fair‑value band 0.0258 SGD – 0.0286 SGD · the 0.0280 SGD price screens above the 0.0258 SGD fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Singapore Institute of Advanced Medicine Holdings (9G2) currently trades at 0.0280 SGD, while our model-based Fair Value estimate is 0.0258 SGD — implying the stock looks roughly 8.0% overvalued today. We read business quality at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 16.2M SGD. Revenue declined 0.1% year over year. It earns a return on equity of -51.0%. Net debt stands at 25.4M SGD. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Singapore Institute of Advanced Medicine Holdings Ltd., an investment holding company, provides medical diagnostics and treatments, and radiation therapy and medical oncology services in Singapore. The company offers medical diagnostics and treatments, including cancer-related diagnostics and theragnostic treatments, general diagnostics and health screening, and aesthetic services; and radiation therapy and medical oncology services comprise proton beam therapy, photon radiation therapy, and medical oncology services. It provides clinic and imaging services; manufactures medical research and clinical diagnostic instruments and supplies; and sells pharmaceuticals, surgical products, and consumables. Singapore Institute of Advanced Medicine Holdings Ltd. was incorporated in 2011 and is based in Singapore.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
Singapore Institute of Advanced Medicine Holdings reported revenue of 15.7M SGD in FY2025 versus 13.8M SGD in FY2022, a compound +4.4%/yr. Reported net income was −26.2M SGD in FY2025.
Is 9G2 fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.27 | $8.25 | -27% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.70 MYR | 2.61 MYR | -70% |
| IHHHF IHHHF | $1.71 | $1.26 | -26% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.83 | R$46.94 | +39% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Singapore Institute of Advanced Medicine Holdings (9G2) undervalued?
What is the fair value of 9G2?
What is the quality score of 9G2?
What is the revenue of Singapore Institute of Advanced Medicine Holdings (9G2)?
What is the net profit margin of 9G2?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.